The Safety of Remote DBS Programming System

Parkinson Disease Clinical Trial

Official title:

A Pilot Study to Investigating Safety of A Remote and Wireless Deep Brain Stimulation Programming System for Parkinson's Disease

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT03267550
• Other study ID #: DBS telemedicine
• Status: Withdrawn
• Phase: N/A
• First received: August 23, 2017
• Last updated: March 22, 2018
• Start date: August 8, 2017
• Est. completion date: March 1, 2018

Study information

• Verified date: March 2018
• Source: Ruijin Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Remote programming has significant advantages over conventional programming methods on some issues. This research will test the safety of SceneRay remote and wireless DBS programming system.

Description:

Programming is a crucial aspect of deep brain stimulation (DBS), directly influences the final success of DBS. Optimal programming helps patients achieve maximized control of clinical symptoms and higher life quality. However, there are a number of inadequacies in conventional programming methods. First, the programming probe must come into close contact with the implantable pulse generator (IPG) and test stimulator to complete programming. And during initial postoperative programming, only the parameters of one patient can be ascertained. In addition, the same frequency is typically used in the left and right brain for dual channel IPG. The patient also need to repeatedly travel between their home and the hospital, leading to increased time and expense. Therefore, the investigators developed the SceneRay wireless and remote DBS system to address the outline issues. This system has significant advantages over conventional programming methods on all the issues above. This research will test the safety of this remote and wireless DBS programming system.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: March 1, 2018
• Est. primary completion date: March 1, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Primary PD patients volunteered to receive DBS surgery with SceneRay wireless and remote DBS system,

• Age 18-75 years,

• Achieved optimal control of clinical symptoms after coventional programming for 3-12 months,

• Significant difference in motor function when DBS is switched on/off,

• Good compliance and easy to follow-up,

Exclusion Criteria:

• No significant improvement or clinical efficacy in symptoms after surgery,

• Severe cognitive impairment due to dementia (Mini-Mental State Examination score:

illiteracy <17, elementary school <20, junior high school or above <24) or inability to accurately record in a diary,

• Active psychosis or a history of psychosis,

• Serious heart, liver, or kidney diseases,

• Severe hypertension or orthostatic hypotension, severe diabetes, or diabetes accompanied by brain and cardiovascular diseases,

• Malignant cancer, brain injuries, epilepsy, or other unstable medical conditions,

• Severe alcohol dependence or drug abuse,

• Any situation that may jeopardize the patient's safety or lead to a failure to participate in the study (medical, psychological, social, or georational factors) at present or in the future,

• Participating in other clinical trials,

• Other factors that researchers think may not be suitable for research.

Related Conditions & MeSH terms

• Parkinson Disease

Intervention

Device:
• SceneRay wireless and remote DBS system
Implement therapeutic programming in patients with network coverage at home

Locations

Country	Name	City	State
China	Shanghai Ruijin Hospital Functional Neurosurgery	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Ruijin Hospital

Country where clinical trial is conducted

China, 

References & Publications (5)

Heo MS, Moon HS, Kim HC, Park HW, Lim YH, Paek SH. Fully Implantable Deep Brain Stimulation System with Wireless Power Transmission for Long-term Use in Rodent Models of Parkinson's Disease. J Korean Neurosurg Soc. 2015 Mar;57(3):152-8. doi: 10.3340/jkns.2015.57.3.152. Epub 2015 Mar 20. — View Citation

Hu WH, Zhang K, Meng FG, Ma Y, Zhang JG. Deep brain stimulation in China: present and future. Neuromodulation. 2012 May-Jun;15(3):251-9; discussion 259. doi: 10.1111/j.1525-1403.2012.00439.x. Epub 2012 Feb 29. Review. — View Citation

Li D, Zhang C, Gault J, Wang W, Liu J, Shao M, Zhao Y, Zeljic K, Gao G, Sun B. Remotely Programmed Deep Brain Stimulation of the Bilateral Subthalamic Nucleus for the Treatment of Primary Parkinson Disease: A Randomized Controlled Trial Investigating the Safety and Efficacy of a Novel Deep Brain Stimulation System. Stereotact Funct Neurosurg. 2017;95(3):174-182. doi: 10.1159/000475765. Epub 2017 Jun 2. — View Citation

Perlmutter JS, Mink JW. Deep brain stimulation. Annu Rev Neurosci. 2006;29:229-57. Review. — View Citation

Zhang C, Li D, Zeljic K, Tan H, Ning Y, Sun B. A Remote and Wireless Deep Brain Stimulation Programming System. Neuromodulation. 2016 Jun;19(4):437-9. doi: 10.1111/ner.12448. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The Unified Parkinson's Disease Rating Scale III&IV		Through study completion, an average of 4 months
Primary	Deep Brain Stimulation Programming parameter	Contact selection	Through study completion, an average of 4 months
Primary	Deep Brain Stimulation Programming parameter	Pulse width	Through study completion, an average of 4 months
Primary	Deep Brain Stimulation Programming parameter	Frequency	Through study completion, an average of 4 months
Primary	Deep Brain Stimulation Programming parameter	Amplitude	Through study completion, an average of 4 months
Primary	Serious Adverse Event		Through study completion, an average of 4 months